TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.

Conference activity picks up, with the big one – ASCO – at the end of the month.

Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.

But sasanlimab's use looks set to remain narrow.

The company is stepping back in second-line breast cancer.

At long last luvelta-T is shelved, and Sutro seeks a new focus.

The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.

Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.

A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.

BGB-16673 and BGB-43395 will soon both be in phase 3 trials, BeiGene reveals.